Boston Scientific Corp.

Boston Scientific announced Wednesday its acquisition of chronic pain treatment firm Cosman Medical, as the Marlborough company keeps its eyes set on non-opioid treatments.

Boston Scientific is undertaking a restructuring program that officials say could result in as much as $150 million in savings per year, although the company indicated some employees will be phased out as the company focuses on new areas of growth.

A system from Boston Scientific that can be used in the place of opioids to combat chronic pain has been approved by the U.S. Food and Drug Administration, the company announced Thursday.

Marlborough's Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for two catheters that can be used with the company's Rhythmia Mapping System.

Marlborough's Boston Scientific posted $1.964 billion in sales in its first quarter, eclipsing the company's guidance and representing 13 percent year-over-year growth.

Boston Scientific, the Marlborough medical device manufacturer and developer, announced a voluntary worldwide recall of a device used to remove small blood clots from coronary arteries during thrombectomy procedures.

LAURA MONDANO is now vice president of regulatory affairs at Harvard Apparatus Regenerative Technology in Holliston. In...

Susan Papalia is a researcher with decades of experience. Today, she's a cardiovascular research nurse manager at UMass Medical School. She's also a committed volunteer who supports multiple organizations for both humans and animals in Massachusetts and around New England.

Marlborough's Boston Scientific has partnered with the Mayo Clinic in Minnesota to share intellectual property and stimulate the rapid development of medical devices to address unmet clinical needs.

A major milestone has come for Boston Scientific as co-founder and chairman of the board Pete Nicholas has announced he will retire at the company's annual meeting in May amid further board member shifts.